Literature DB >> 12454100

Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva.

M Murakami1, T Ohtake, R A Dorschner, R L Gallo.   

Abstract

The expression of antimicrobial peptides at epithelial surfaces such as skin, lung, and intestine is thought to provide protection against infection. Cathelicidin antimicrobial peptides are essential for the protection of skin against invasive bacterial infection. To determine if cathelicidins are also present in the oral cavity, we examined the expression of both mRNA and protein in mice and human saliva. The murine cathelicidin (CRAMP) was detected in the adult by reverse-transcription/polymerase chain-reaction (RT-PCR), and in embryonic, newborn, and adult tissues by in situ hybridization and immunohistochemistry. CRAMP mRNA and protein were localized to the salivary glands, specifically in acinar cells of the submandibular gland and palatine minor glands, as well as in lingual epithelium and palatal mucosa. In man, the human cathelicidin LL-37 was detected in human saliva by Western blotting. These results indicate that cathelicidins are present in the salivary system, in some oral epithelia, and in saliva, contributing to broad-spectrum defense of the oral cavity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454100     DOI: 10.1177/154405910208101210

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  58 in total

1.  Labial Salivary Glands in Infants: Histochemical Analysis of Cytoskeletal and Antimicrobial Proteins.

Authors:  Mechthild Stoeckelhuber; Denys J Loeffelbein; Bernhard Olzowy; Christoph Schmitz; Steffen Koerdt; Marco R Kesting
Journal:  J Histochem Cytochem       Date:  2016-08       Impact factor: 2.479

2.  A member of the cathelicidin family of antimicrobial peptides is produced in the upper airway of the chinchilla and its mRNA expression is altered by common viral and bacterial co-pathogens of otitis media.

Authors:  Glen McGillivary; William C Ray; Charles L Bevins; Robert S Munson; Lauren O Bakaletz
Journal:  Mol Immunol       Date:  2006-11-20       Impact factor: 4.407

3.  Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane.

Authors:  Alice L den Hertog; Jan van Marle; Henk A van Veen; Wim Van't Hof; Jan G M Bolscher; Enno C I Veerman; Arie V Nieuw Amerongen
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

Review 4.  Paneth cell alpha-defensins: peptide mediators of innate immunity in the small intestine.

Authors:  Andre J Ouellette
Journal:  Springer Semin Immunopathol       Date:  2005-06-02

Review 5.  Lipoproteins of bacterial pathogens.

Authors:  A Kovacs-Simon; R W Titball; S L Michell
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

6.  Purinergic receptors in the endocrine and exocrine pancreas.

Authors:  I Novak
Journal:  Purinergic Signal       Date:  2007-12-11       Impact factor: 3.765

Review 7.  Host defense peptides in the oral cavity and the lung: similarities and differences.

Authors:  G Diamond; N Beckloff; L K Ryan
Journal:  J Dent Res       Date:  2008-10       Impact factor: 6.116

8.  Involvement of the P2X7 purinergic receptor and c-Jun N-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin E2 induction by LL-37.

Authors:  Pareena Chotjumlong; Jan G Bolscher; Kamran Nazmi; Vichai Reutrakul; Chayarop Supanchart; Worakanya Buranaphatthana; Suttichai Krisanaprakornkit
Journal:  J Innate Immun       Date:  2012-10-23       Impact factor: 7.349

9.  LL-37 disrupts the Kaposi's sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells.

Authors:  David C Brice; Zsolt Toth; Gill Diamond
Journal:  Antiviral Res       Date:  2018-08-02       Impact factor: 5.970

10.  Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.

Authors:  Robert Bucki; Dorota B Namiot; Zbigniew Namiot; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2008-05-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.